
Valentina Gandin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7392260/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Advances in Copper Complexes as Anticancer Agents. Chemical Reviews, 2014, 114, 815-862.	47.7	1,375
2	Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coordination Chemistry Reviews, 2009, 253, 1692-1707.	18.8	513
3	Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biology and Medicine, 2007, 42, 872-881.	2.9	367
4	Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochemical Pharmacology, 2010, 79, 90-101.	4.4	216
5	Pt(<scp>iv</scp>) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chemical Science, 2016, 7, 2381-2391.	7.4	155
6	A novel copper complex induces paraptosis in colon cancer cellsâ€, <i>via</i> â€,the activation of ER stress signalling. Journal of Cellular and Molecular Medicine, 2012, 16, 142-151.	3.6	128
7	Purification of Mitochondrial Thioredoxin Reductase and Its Involvement in the Redox Regulation of Membrane Permeability. Free Radical Biology and Medicine, 1998, 24, 370-376.	2.9	125
8	Fluorescent silver(i) and gold(i)–N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. Metallomics, 2013, 5, 1006.	2.4	121
9	Triple action Pt(<scp>iv</scp>) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chemical Science, 2018, 9, 4299-4307.	7.4	121
10	In Vitro Antitumor Activity of the Water Soluble Copper(I) Complexes Bearing the Tris(hydroxymethyl)phosphine Ligand. Journal of Medicinal Chemistry, 2008, 51, 798-808.	6.4	117
11	Synthesis, Characterization, and in Vitro Antitumor Properties of Tris(hydroxymethyl)phosphine Copper(I) Complexes Containing the New Bis(1,2,4-triazol-1-yl)acetate Ligand. Journal of Medicinal Chemistry, 2006, 49, 7317-7324.	6.4	115
12	In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands. Journal of Inorganic Biochemistry, 2011, 105, 232-240.	3.5	101
13	<i>In Vitro</i> and <i>in Vivo</i> Anticancer Activity of Copper(I) Complexes with Homoscorpionate Tridentate Tris(pyrazolyl)borate and Auxiliary Monodentate Phosphine Ligands. Journal of Medicinal Chemistry, 2014, 57, 4745-4760.	6.4	100
14	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie - International Edition, 2017, 56, 11539-11544.	13.8	100
15	Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors. Free Radical Biology and Medicine, 2018, 127, 62-79.	2.9	97
16	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays. MedChemComm, 2011, 2, 50-54.	3.4	94
17	Synthesis and Biological Activity of Ester- and Amide-Functionalized Imidazolium Salts and Related Water-Soluble Coinage Metal N-Heterocyclic Carbene Complexes. Inorganic Chemistry, 2012, 51, 9873-9882.	4.0	93
18	InÂvitro and inÂvivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target. European Journal of Medicinal Chemistry, 2020, 194, 112266.	5.5	85

#	Article	IF	CITATIONS
19	Novel Mixed-Ligand Copper(I) Complexes: Role of Diimine Ligands on Cytotoxicity and Genotoxicity. Journal of Medicinal Chemistry, 2013, 56, 7416-7430.	6.4	72
20	Synthesis and in vitro antitumor activity of water soluble sulfonate- and ester-functionalized silver(I) N-heterocyclic carbene complexes. Journal of Inorganic Biochemistry, 2013, 129, 135-144.	3.5	70
21	Revisiting [PtCl ₂ (<i>cis</i> -1,4-DACH)]: An Underestimated Antitumor Drug with Potential Application to the Treatment of Oxaliplatin-Refractory Colorectal Cancer. Journal of Medicinal Chemistry, 2012, 55, 7182-7192.	6.4	65
22	Neutral and charged phosphine/scorpionate copper(I) complexes: Effects of ligand assembly on their antiproliferative activity. European Journal of Medicinal Chemistry, 2013, 59, 218-226.	5.5	65
23	Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radical Biology and Medicine, 2009, 47, 710-721.	2.9	59
24	Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Scientific Reports, 2016, 6, 29367.	3.3	56
25	Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA). Journal of Inorganic Biochemistry, 2009, 103, 1644-1651.	3.5	55
26	Homoleptic phosphino copper(<scp>i</scp>) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity. Metallomics, 2015, 7, 1497-1507.	2.4	54
27	Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents. Molecules, 2015, 20, 12732-12756.	3.8	53
28	Expanding the Arsenal of Pt ^{IV} Anticancer Agents: Multiâ€action Pt ^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie - International Edition, 2019, 58, 18218-18223.	13.8	47
29	Mitochondrial Thioredoxin System as a Modulator of Cyclophilin D Redox State. Scientific Reports, 2016, 6, 23071.	3.3	46
30	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. Scientific Reports, 2017, 7, 13936.	3.3	45
31	Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(<scp>iv</scp>) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Transactions, 2017, 46, 7005-7019.	3.3	43
32	Nitroimidazole and glucosamine conjugated heteroscorpionate ligands and related copper(ii) complexes. Syntheses, biological activity and XAS studies. Dalton Transactions, 2011, 40, 9877.	3.3	42
33	Chemistry and Biological Activity of Platinum Amidine Complexes. ChemMedChem, 2011, 6, 1172-1183.	3.2	41
34	Synthesis, characterization and cytotoxic activity of novel copper(II) complexes with aroylhydrazone derivatives of 2-Oxo-1,2-dihydrobenzo[h]quinoline-3-carbaldehyde. Journal of Inorganic Biochemistry, 2018, 182, 18-28.	3.5	41
35	Cisplatinum and Transplatinum Complexes with Benzyliminoether Ligands; Synthesis, Characterization, Structureâ^'Activity Relationships, and In Vitro and In Vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 2007, 50, 4775-4784.	6.4	40
36	An unsymmetric cisplatin-based Pt(<scp>iv</scp>) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Transactions, 2017, 46, 14174-14185.	3.3	39

#	Article	IF	CITATIONS
37	Insights into the cytotoxic activity of the phosphane copper(I) complex [Cu(thp)4][PF6]. Journal of Inorganic Biochemistry, 2016, 165, 80-91.	3.5	38
38	Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. Scientific Reports, 2017, 7, 3751.	3.3	38
39	Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. Journal of Inorganic Biochemistry, 2017, 177, 1-7.	3.5	38
40	DNA damage and induction of apoptosis in pancreatic cancer cells by a new dinuclear bis(triazacyclonane) copper complex. Journal of Inorganic Biochemistry, 2015, 145, 101-107.	3.5	35
41	Exploring the C^N^C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes. Bioorganic and Medicinal Chemistry, 2017, 25, 5452-5460.	3.0	32
42	Tamoxifen-like metallocifens target the thioredoxin system determining mitochondrial impairment leading to apoptosis in Jurkat cells. Metallomics, 2017, 9, 949-959.	2.4	30
43	A Cu(<scp>ii</scp>) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights. Chemical Communications, 2017, 53, 134-137.	4.1	30
44	Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?. Journal of Medicinal Chemistry, 2021, 64, 11364-11378.	6.4	30
45	A New Class of Antitumor <i>trans</i> -Amine-Amidine-Pt(II) Cationic Complexes: Influence of Chemical Structure and Solvent on in Vitro and in Vivo Tumor Cell Proliferation. Journal of Medicinal Chemistry, 2010, 53, 6210-6227.	6.4	29
46	Glucose-Coated Superparamagnetic Iron Oxide Nanoparticles Prepared by Metal Vapour Synthesis Are Electively Internalized in a Pancreatic Adenocarcinoma Cell Line Expressing GLUT1 Transporter. PLoS ONE, 2015, 10, e0123159.	2.5	28
47	The relationship between the electrospray ionization behaviour and biological activity of some phosphino Cu(I) complexes. Rapid Communications in Mass Spectrometry, 2010, 24, 1610-1616.	1.5	27
48	Encapsulation of lipophilic kiteplatin Pt(<scp>iv</scp>) prodrugs in PLGA-PEG micelles. Dalton Transactions, 2016, 45, 13070-13081.	3.3	27
49	Easily Available, Amphiphilic Diiron Cyclopentadienyl Complexes Exhibit in Vitro Anticancer Activity in 2D and 3D Human Cancer Cells through Redox Modulation Triggered by CO Release. Chemistry - A European Journal, 2021, 27, 10169-10185.	3.3	25
50	The first waterâ€soluble copper(I) complexes bearing sulfonated imidazole―and benzimidazoleâ€derived Nâ€heterocyclic carbenes: Synthesis and anticancer studies. Applied Organometallic Chemistry, 2018, 32, e4185.	3.5	23
51	<i>trans</i> , <i>cis</i> , <i>cis</i> â€Bis(benzoato)dichlorido(cyclohexaneâ€1 <i>R</i> ,2 <i>R</i> â€diamine)platinu a Prodrug Candidate for the Treatment of Oxaliplatinâ€Refractory Colorectal Cancer. ChemMedChem, 2014, 9, 1299-1305.	ım(IV): 3.2	22
52	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie, 2017, 129, 11697-11702.	2.0	22
53	Syntheses and biological studies of nitroimidazole conjugated heteroscorpionate ligands and related Cu(I) and Cu(II) complexes. Journal of Inorganic Biochemistry, 2018, 187, 33-40.	3.5	22
54	Dual-acting antitumor Pt(<scp>iv</scp>) prodrugs of kiteplatin with dichloroacetate axial ligands. Dalton Transactions, 2018, 47, 7144-7158.	3.3	21

#	Article	IF	CITATIONS
55	Synthesis and Cytotoxic Activity Evaluation of New Cu(I) Complexes of Bis(pyrazol-1-yl) Acetate Ligands Functionalized with an NMDA Receptor Antagonist. International Journal of Molecular Sciences, 2020, 21, 2616.	4.1	20
56	Cytotoxicity of cis-platinum(II) cycloaliphatic amidine complexes: Ring size and solvent effects on the biological activity. Journal of Inorganic Biochemistry, 2009, 103, 1113-1119.	3.5	19
57	A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 3775.	4.1	19
58	Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. Journal of Inorganic Biochemistry, 2016, 160, 85-93.	3.5	18
59	Syntheses and Biological Studies of Cu(II) Complexes Bearing Bis(pyrazol-1-yl)- and Bis(triazol-1-yl)-acetato Heteroscorpionate Ligands. Molecules, 2019, 24, 1761.	3.8	18
60	Anticancer activity, DNA binding and cell mechanistic studies of estrogen-functionalised Cu(II) complexes. Journal of Biological Inorganic Chemistry, 2020, 25, 49-60.	2.6	18
61	Synthesis, Characterization and Biological Activity of Novel Cu(II) Complexes of 6-Methyl-2-Oxo-1,2-Dihydroquinoline-3-Carbaldehyde-4n-Substituted Thiosemicarbazones. Molecules, 2020, 25, 1868.	3.8	18
62	Antiproliferative Homoleptic and Heteroleptic Phosphino Silver(I) Complexes: Effect of Ligand Combination on Their Biological Mechanism of Action. Molecules, 2020, 25, 5484.	3.8	17
63	In vitro antitumor activity of water-soluble copper(I) complexes with diimine and monodentate phosphine ligands. Arabian Journal of Chemistry, 2020, 13, 998-1010.	4.9	16
64	Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions. International Journal of Molecular Sciences, 2018, 19, 2050.	4.1	15
65	Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance. International Journal of Molecular Sciences, 2020, 21, 2325.	4.1	12
66	Expanding the Arsenal of Pt ^{IV} Anticancer Agents: Multiâ€action Pt ^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie, 2019, 131, 18386-18391.	2.0	11
67	Pt(<scp>iv</scp>) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. Dalton Transactions, 2021, 50, 4663-4672.	3.3	11
68	Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects. Inorganic Chemistry, 2022, 61, 4919-4937.	4.0	11
69	Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes. Neurotoxicity Research, 2018, 34, 93-108.	2.7	10
70	Phytochemical Fingerprinting and In Vitro Bioassays of the Ethnomedicinal Fern Tectaria coadunata (J.) Tj ETQq() 0	Overlock 10
71	Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration. International Journal of Molecular Sciences, 2022, 23, 7081.	4.1	9

Possible Chelating Agents for Iron and Aluminium – 4â€Hydroxyâ€5â€methyl†and 4â€Hydroxyâ€1,5â€dimethylâ€3â€pyridinecarboxylic Acid. European Journal of Inorganic Chemistry, 2013, 2013, 2.0 8 1310-1319.

#	Article	IF	CITATIONS
73	Phosphine copper(I) complexes as anticancer agents: biological characterization. Part II. , 2019, , 83-107.		8
74	Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. Journal of Controlled Release, 2021, 340, 318-330.	9.9	8
75	Antiproliferative activity of nickel(II), palladium(II) and zinc(II) thiosemicarbazone complexes. Inorganica Chimica Acta, 2022, 533, 120779.	2.4	8
76	Sesquiterpene rich essential oil from Nepalese Bael tree (Aegle marmelos (L.) Correa) as potential antiproliferative agent. Fìtoterapìâ, 2019, 138, 104266.	2.2	7
77	A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring. RSC Advances, 2019, 9, 32448-32452.	3.6	7
78	Effect of chirality on the anticancer activity of Pt(<scp>ii</scp>) and Pt(<scp>iv</scp>) complexes containing 1 <i>R</i> ,2 <i>R</i> and 1 <i>S</i> ,2 <i>S</i> enantiomers of the <i>trans</i> -1,2-diamino-4-cyclohexene ligand (DACHEX), an analogue of diaminocyclohexane used in oxaliplatin. Dalton Transactions, 2021, 50, 15655-15668.	3.3	7
79	A Pt(IV) prodrug of kiteplatin with the bone-targeting pyrophosphate ligand. Inorganica Chimica Acta, 2019, 494, 98-104.	2.4	6
80	Phosphine–copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I. , 2019, , 61-82.		6